Rituximab induced hypogammaglobulinemia
Dr. Leena Ahmed, PGY2
Supervisor: Dr. Jenny Garkaby, Assistant Professor, Pediatrics, McMaster University
Rituximab, a monoclonal antibody targeting CD20 on B cells, is commonly used in the treatment of autoimmune, hematological, and oncological disorders. However, its impact on B-cell function can lead to secondary hypogammaglobulinemia, increasing patients’ susceptibility to infections and immune system irregularities. While this condition was once considered temporary, there is growing evidence of persistent hypogammaglobulinemia in some individuals after rituximab treatment. Despite the recognized risk, consistent monitoring of immunoglobulin levels before and after treatment is not always practiced, and there is limited guidance on identifying patients at higher risk of long-term hypogammaglobulinemia. This study underscores the importance of pre-treatment immunoglobulin testing and regular post-treatment monitoring to better manage and mitigate this risk.
macpedsrrt.ca 